C57Bl/6 (B6) mice and mice of a congeneic strain, B6S, differ in the proportions of erythroid progenitor cells (BFU-E) typically seen in DNA synthesis in in vivo cell suicide assays, and bone marrow supernatants (MS) prepared from B6 mice can inhibit BFU-E cycling in vitro. Using in vitro BFU-E DNA synthesis assays and a model system of BFU-E in culture (DA-1 cells) as screening methods for the detection of inhibitors of BFU-E cycling, we have purified the protein that is apparently responsible for the inhibitory effects of MS on progenitor cells and that is also an antagonist of the stimulatory effects of interleukin-3 (IL-3) on DA-1 cell proliferation in culture. We have identified this protein as the Cu,Zn-containing form of the antioxidant enzyme superoxide dismutase (SOD), which is normally present in large amounts in erythrocytes. MS from B6S mice does not inhibit BFU-E DNA synthesis. However, measurements of SOD activity showed no differences between B6 and B6S mice; thus the difference between the effects of B6S-MS and B6-MS is not due to differences in the levels of SOD present. The inhibitory effects of SOD on BFU-E in vitro are opposed by the stimulatory effects of IL-3 in a dose-dependent manner, and similar interactions between stimulatory and inhibitory factors also appear to determine the effects of mouse-derived preparations on erythroid cells. If the interactions seen in vitro are applicable to the state in vivo, SOD may be a constitutive inhibitor of erythroid progenitor cell cycling in mice, acting in opposition to stimulatory factors whose expression varies in response to genetic and physiological influences.
No takes yet. Share an insight, caveat, or question.
Pluthero et al. (1991) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: